Literature DB >> 23248261

IL-33 induces a hyporesponsive phenotype in human and mouse mast cells.

Mi-Yeon Jung1, Daniel Smrž, Avanti Desai, Geethani Bandara, Tomonobu Ito, Shoko Iwaki, Jeong-Han Kang, Marcus V Andrade, Susana C Hilderbrand, Jared M Brown, Michael A Beaven, Dean D Metcalfe, Alasdair M Gilfillan.   

Abstract

IL-33 is elevated in afflicted tissues of patients with mast cell (MC)-dependent chronic allergic diseases. Based on its acute effects on mouse MCs, IL-33 is thought to play a role in the pathogenesis of allergic disease through MC activation. However, the manifestations of prolonged IL-33 exposure on human MC function, which best reflect the conditions associated with chronic allergic disease, are unknown. In this study, we found that long-term exposure of human and mouse MCs to IL-33 results in a substantial reduction of MC activation in response to Ag. This reduction required >72 h exposure to IL-33 for onset and 1-2 wk for reversion following IL-33 removal. This hyporesponsive phenotype was determined to be a consequence of MyD88-dependent attenuation of signaling processes necessary for MC activation, including Ag-mediated calcium mobilization and cytoskeletal reorganization, potentially as a consequence of downregulation of the expression of phospholipase Cγ(1) and Hck. These findings suggest that IL-33 may play a protective, rather than a causative, role in MC activation under chronic conditions and, furthermore, reveal regulated plasticity in the MC activation phenotype. The ability to downregulate MC activation in this manner may provide alternative approaches for treatment of MC-driven disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23248261      PMCID: PMC3538948          DOI: 10.4049/jimmunol.1201576

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.

Authors:  Matthew R Silver; Alexander Margulis; Nancy Wood; Samuel J Goldman; Marion Kasaian; Divya Chaudhary
Journal:  Inflamm Res       Date:  2009-09-18       Impact factor: 4.575

Review 2.  IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma.

Authors:  D E Smith
Journal:  Clin Exp Allergy       Date:  2009-11-03       Impact factor: 5.018

3.  Measuring mast cell mediator release.

Authors:  Hye Sun Kuehn; Madeleine Radinger; Alasdair M Gilfillan
Journal:  Curr Protoc Immunol       Date:  2010-11

4.  Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells.

Authors:  Hye Sun Kuehn; Madeleine Rådinger; Jared M Brown; Khaled Ali; Bart Vanhaesebroeck; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Cell Sci       Date:  2010-06-29       Impact factor: 5.285

5.  Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33.

Authors:  Marcus V Andrade; Shoko Iwaki; Catherine Ropert; Ricardo T Gazzinelli; Jose R Cunha-Melo; Michael A Beaven
Journal:  Eur J Immunol       Date:  2011-02-10       Impact factor: 5.532

Review 6.  Regulation of mast cell responses in health and disease.

Authors:  Alasdair M Gilfillan; Michael A Beaven
Journal:  Crit Rev Immunol       Date:  2011       Impact factor: 2.214

7.  IL-33 is produced by mast cells and regulates IgE-dependent inflammation.

Authors:  Chia-Lin Hsu; Colleen V Neilsen; Paul J Bryce
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.240

Review 8.  Mechanisms of mast cell signaling in anaphylaxis.

Authors:  Dean D Metcalfe; Richard D Peavy; Alasdair M Gilfillan
Journal:  J Allergy Clin Immunol       Date:  2009-10       Impact factor: 10.793

9.  The cytokine interleukin-33 mediates anaphylactic shock.

Authors:  Peter N Pushparaj; Hwee Kee Tay; Shiau Chen H'ng; Nick Pitman; Damo Xu; Andrew McKenzie; Foo Y Liew; Alirio J Melendez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

10.  IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Authors:  Theoharis C Theoharides; Bodi Zhang; Duraisamy Kempuraj; Michael Tagen; Magdalini Vasiadi; Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Dimitris Kalogeromitros; Shahrzad Asadi; Nikolaos Stavrianeas; Erika Peterson; Susan Leeman; Pio Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

View more
  18 in total

Review 1.  Potential effector and immunoregulatory functions of mast cells in mucosal immunity.

Authors:  L L Reber; R Sibilano; K Mukai; S J Galli
Journal:  Mucosal Immunol       Date:  2015-02-11       Impact factor: 7.313

Review 2.  Mast cell activity in the healing wound: more than meets the eye?

Authors:  Brian C Wulff; Traci A Wilgus
Journal:  Exp Dermatol       Date:  2013-06-27       Impact factor: 3.960

Review 3.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

Review 4.  The immunology of food allergy.

Authors:  Laura K Johnston; Karen B Chien; Paul J Bryce
Journal:  J Immunol       Date:  2014-03-15       Impact factor: 5.422

Review 5.  Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation.

Authors:  Rohit Divekar; Hirohito Kita
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

6.  Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Authors:  Geethani Bandara; Michael A Beaven; Ana Olivera; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Eur J Immunol       Date:  2015-09-09       Impact factor: 5.532

Review 7.  Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's Perspective.

Authors:  Tae Young Jang; Young Hyo Kim
Journal:  Int Neurourol J       Date:  2015-09-22       Impact factor: 2.835

8.  Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria.

Authors:  Wei Lin; Qiongyan Zhou; Chunbo Liu; Mengxia Ying; Suling Xu
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

9.  IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells.

Authors:  Claire Galand; Juan Manuel Leyva-Castillo; Juhan Yoon; Alex Han; Margaret S Lee; Andrew N J McKenzie; Michael Stassen; Michiko K Oyoshi; Fred D Finkelman; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2016-06-02       Impact factor: 10.793

10.  IL-33 promotes MHC class II expression in murine mast cells.

Authors:  Tomonobu Ito; Chizu Egusa; Tatsuo Maeda; Takafumi Numata; Nobuhiro Nakano; Chiharu Nishiyama; Ryoji Tsuboi
Journal:  Immun Inflamm Dis       Date:  2015-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.